SAN JOSE, Calif., Nov. 2, 2017 /PRNewswire/ -- Intermolecular,
Inc. (NASDAQ: IMI) today reported results for its Third Quarter
ended September 30, 2017.
Results Highlights:
- Positive third quarter adjusted EBITDA on 7% sequential revenue
growth
- Third quarter total revenue of $8.6
million
- Five new contracts signed during the quarter
"We are delighted to report our achievement of positive adjusted
EBITDA ahead of schedule," said Chris
Kramer, president and CEO of Intermolecular. "Our
return to profitability is due to the combination of expanding
relationships with existing customers, new programs with new
customers and disciplined cost control. We are building
strong momentum in the market which validates the important
position we have established as a leading innovator in materials
science, particularly for the semiconductor industry."
Third Quarter Fiscal 2017 Results
Revenue for the third quarter of 2017 was $8.6 million, up 7% compared to second quarter
2017 revenue of $8.1 million and down
18% compared to $10.6 million in the
same period a year ago. GAAP net loss for the third quarter was
$(1.8) million, or $(0.04) per share, compared to a net loss of
$(2.9) million in the second quarter
of 2017, or $(0.06) per share and a
net loss of $(6.8) million, or
$(0.14) per share, in the same period
a year ago. Cash and investments were $27.1
million at the third quarter of 2017, an increase of
$0.1 million compared with the second
quarter of 2017.
Non-GAAP net loss for the third quarter was $(1.6) million, or $(0.03) per share compared to a non-GAAP net loss
of $(2.5) million, or $(0.05) per share, in the prior quarter and
$(5.9) million, or $(0.12) per share in the same period a year
ago.
Adjusted EBITDA for the third quarter was $0.1 million, compared to an adjusted EBITDA loss
of $(1.0) million in the second
quarter of 2017 and an adjusted EBITDA loss of $(0.9) million in the same period a year
ago.
Outlook for Fourth Quarter of 2017
The following statements are based on Intermolecular's current
expectations for the fourth quarter of the fiscal year ended
December 31, 2017. The following
statements are forward-looking, and actual results could differ
materially depending on market conditions and the factors set forth
under "Forward-Looking Statements" below. Intermolecular does not
plan to update, nor does it undertake any obligation to update,
this outlook in the future.
- Intermolecular projects revenue in the range of $9.4 million to $9.9 million.
- GAAP net loss is projected between $(1.0) million and $(1.5) million, or between
$(0.02) to $(0.03) per share, on
approximately 49.6 million shares outstanding
- Non-GAAP net loss, which excludes stock-based compensation
expense, is projected between $(0.7) million
and $(1.2) million, or between $(0.01) to $(0.03) per share
- Adjusted EBITDA is projected to be between $0.5 million and $1.0 million.
Intermolecular reports revenue, cost of revenue, gross margin,
operating income (loss), net income (loss) and earnings (loss) per
share in accordance with U.S. generally accepted accounting
principles (GAAP) and additionally on a non-GAAP basis. A
reconciliation of the non-GAAP financial measures with the most
directly comparable GAAP measures, as well as a description of the
items excluded from the non-GAAP measures, is included in the
financial statements portion of this press release. Please refer to
"Reconciliation of GAAP to Non-GAAP Financial Measures" and
"Reconciliation of GAAP Net Loss to Non-GAAP Net Loss" below.
Conference Call Today
Intermolecular will host a conference call and simultaneous
audio-only webcast at 5:00 p.m. Eastern
Time/2:00 p.m. Pacific Time
today with Chris Kramer, CEO and
president, and Bill Roeschlein,
Chief Financial Officer, for Intermolecular.
The call can be accessed by dialing (877) 251-1860;
international callers should dial (224) 357-2386. Please
dial-in ten minutes prior to the scheduled conference call time.
The conference ID is 95697975. A live and archived webcast (audio
only) of the call will be available on Intermolecular's Website at
http://ir.intermolecular.com for up to 30 days after the
call.
About Intermolecular, Inc.
Intermolecular® is the trusted partner for advanced materials
innovation. Advanced materials are at the core of
innovation in the 21st century for a wide range of
industries including semiconductors, consumer electronics,
automotive and aerospace. With its substantial materials expertise;
accelerated learning and experimentation platform; and information
and analytics infrastructure, Intermolecular has a ten-year track
record helping leading companies accelerate and de-risk materials
innovation.
"Intermolecular" and the Intermolecular logo are registered
trademarks; all rights reserved. Learn more at
www.intermolecular.com.
Forward-Looking Statements
Statements made in this press release and the earnings call
referencing the press release that are not statements of historical
fact are forward-looking statements. Forward-looking statements are
subject to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
commonly identified by words such as "would," "may," "expects,"
"believes," "plans," "intends," "projects" and other terms with
similar meaning. Investors are cautioned that the forward-looking
statements in this document are based on current beliefs,
assumptions and expectations, speak only as of the date of this
document and involve risks and uncertainties that could cause
actual results to differ materially from current expectations. Such
statements are subject to certain known and unknown risks and
uncertainties, many of which are difficult to predict and generally
beyond Intermolecular's control, that could cause actual results
and other future events to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. Material factors that could cause actual results to
differ materially from current expectations include, without
limitation, the following: our ability to productize our workflows
with existing and future customers; expectations regarding our
future revenue, cash flow and GAAP and non-GAAP net income or loss;
financial condition; the ability of our new business model to
generate profits and long-term shareholder returns; the extent to
which technology developed in collaboration with our customers will
continue to remain on the critical path and have significant value
for such customers and us as well as the industry as a whole; and
anticipated growth in our current markets through expansion of
existing customer programs and the entry into other engagements
with new customers. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially from expectations, including but not limited to: our
ability to execute on our strategy, prove our business model and
remain technologically competitive in rapidly evolving industry
conditions; commercial acceptance of our HPC platform and
methodology as effective R&D tools; our ability to achieve and
sustain profitability; the ability of our customers to achieve
their announced product roadmaps in a timely manner; the extent to
which we are able to successfully extend and expand relationships
with existing customers; our ability to manage the growth of our
business; the rapid technology changes and volatility of the
customers and industries we serve; our potential need for future
capital to finance our operations; and other risks described in our
most recent annual report on Form 10-K as updated by our quarterly
reports on Form 10-Q and other filings with the Securities and
Exchange Commission available at www.sec.gov, particularly in the
sections titled "Risk Factors." All forward-looking statements are
based on management's current estimates, projections and
assumptions, and we assume no obligation to update them.
Non-GAAP Financial Measures
To supplement the financial data presented on a GAAP basis, we
also disclose certain non-GAAP financial measures, which exclude
the effect of stock-based compensation expense. These non-GAAP
financial measures are not prepared in accordance with GAAP, do not
serve as an alternative to GAAP and may be calculated differently
than non-GAAP financial information disclosed by other companies.
These results should only be used to evaluate our results of
operations in conjunction with the corresponding GAAP measures. We
believe that our non-GAAP financial information provides useful
information to management and investors regarding financial and
business trends relating to our financial condition and results of
operations because the non-GAAP measures exclude charges that
management considers to be outside of Intermolecular's core
operating results. We believe that the non-GAAP measures of
revenue, cost of net revenue, gross profit, gross margin, operating
(loss) income, net (loss) income, earnings per share and net (loss)
income per share, viewed in combination with our financial results
calculated in accordance with GAAP, provide investors with
additional perspective and a more meaningful understanding of our
ongoing operating performance. In addition, management uses these
non-GAAP measures to review and assess financial performance, to
determine executive officer incentive compensation and to plan and
forecast performance in future periods.
|
Intermolecular, Inc.
|
|
Condensed
Consolidated Statements of Operations
|
|
(In thousands,
except share and per share amounts, Unaudited)
|
|
|
|
Three Months
Ended
September 30,
|
|
|
Nine Months
Ended
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Program
revenue
|
|
$
|
6,869
|
|
|
$
|
8,844
|
|
|
$
|
20,160
|
|
|
$
|
30,857
|
|
|
Licensing and royalty
revenue
|
|
|
1,753
|
|
|
|
1,730
|
|
|
|
6,495
|
|
|
|
5,964
|
|
|
Total
revenue
|
|
|
8,622
|
|
|
|
10,574
|
|
|
|
26,655
|
|
|
|
36,821
|
|
|
Cost of
revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of program
revenue
|
|
|
2,864
|
|
|
|
3,431
|
|
|
|
8,106
|
|
|
|
12,284
|
|
|
Cost of licensing and
royalty revenue
|
|
|
11
|
|
|
|
25
|
|
|
|
303
|
|
|
|
100
|
|
|
Total cost of
revenue
|
|
|
2,875
|
|
|
|
3,456
|
|
|
|
8,409
|
|
|
|
12,384
|
|
|
Gross
profit
|
|
|
5,747
|
|
|
|
7,118
|
|
|
|
18,246
|
|
|
|
24,437
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
|
4,835
|
|
|
|
8,451
|
|
|
|
17,328
|
|
|
|
22,279
|
|
|
Sales and
marketing
|
|
|
874
|
|
|
|
1,792
|
|
|
|
3,285
|
|
|
|
5,866
|
|
|
General and
administrative
|
|
|
2,000
|
|
|
|
2,667
|
|
|
|
7,225
|
|
|
|
7,936
|
|
|
Restructuring
charges
|
|
|
—
|
|
|
|
1,120
|
|
|
|
1,351
|
|
|
|
1,120
|
|
|
Total operating
expenses
|
|
|
7,709
|
|
|
|
14,030
|
|
|
|
29,189
|
|
|
|
37,201
|
|
|
Loss from
operations
|
|
|
(1,962)
|
|
|
|
(6,912)
|
|
|
|
(10,943)
|
|
|
|
(12,764)
|
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
(expense), net
|
|
|
70
|
|
|
|
51
|
|
|
|
182
|
|
|
|
123
|
|
|
Other income
(expense), net
|
|
|
64
|
|
|
|
89
|
|
|
|
243
|
|
|
|
204
|
|
|
Total other income
(expense), net
|
|
|
134
|
|
|
|
140
|
|
|
|
425
|
|
|
|
327
|
|
|
Loss before provision
for income taxes
|
|
|
(1,828)
|
|
|
|
(6,772)
|
|
|
|
(10,518)
|
|
|
|
(12,437)
|
|
|
Provision for income
taxes
|
|
|
—
|
|
|
|
3
|
|
|
|
1
|
|
|
|
7
|
|
|
Net loss
|
|
$
|
(1,828)
|
|
|
$
|
(6,775)
|
|
|
$
|
(10,519)
|
|
|
$
|
(12,444)
|
|
|
Net loss per share,
basic and diluted
|
|
$
|
(0.04)
|
|
|
$
|
(0.14)
|
|
|
$
|
(0.21)
|
|
|
$
|
(0.25)
|
|
|
Weighted-average
number of shares used in computing net loss per share, basic
and
diluted
|
|
|
49,554,701
|
|
|
|
49,466,137
|
|
|
|
49,543,014
|
|
|
|
49,366,982
|
|
|
Intermolecular, Inc.
|
|
Condensed
Consolidated Balance Sheets
|
|
(In thousands,
Unaudited)
|
|
|
|
As of
September 30,
2017
|
|
|
As of
December 31,
2016
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
9,887
|
|
|
$
|
5,759
|
|
|
Short-term
investments
|
|
|
14,852
|
|
|
|
20,035
|
|
|
Total cash, cash
equivalents and short-term investments
|
|
|
24,739
|
|
|
|
25,794
|
|
|
Accounts
receivable
|
|
|
3,476
|
|
|
|
5,063
|
|
|
Prepaid expenses and
other current assets
|
|
|
1,017
|
|
|
|
1,397
|
|
|
Total current
assets
|
|
|
29,232
|
|
|
|
32,254
|
|
|
Long-term
investments
|
|
|
2,409
|
|
|
|
1,995
|
|
|
Materials
inventory
|
|
|
2,995
|
|
|
|
3,357
|
|
|
Property and
equipment, net
|
|
|
7,096
|
|
|
|
10,964
|
|
|
Intangible assets,
net
|
|
|
3,081
|
|
|
|
4,001
|
|
|
Other
assets
|
|
|
577
|
|
|
|
597
|
|
|
Total
assets
|
|
$
|
45,390
|
|
|
$
|
53,168
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
1,014
|
|
|
$
|
309
|
|
|
Accrued
liabilities
|
|
|
1,046
|
|
|
|
1,451
|
|
|
Accrued compensation
and employee benefits
|
|
|
2,564
|
|
|
|
1,663
|
|
|
Deferred
revenue
|
|
|
2,018
|
|
|
|
1,533
|
|
|
Total current
liabilities
|
|
|
6,642
|
|
|
|
4,956
|
|
|
Other long-term
liabilities
|
|
|
3,022
|
|
|
|
3,216
|
|
|
Total
liabilities
|
|
|
9,664
|
|
|
|
8,172
|
|
|
Stockholders'
equity:
|
|
|
|
|
|
|
|
|
|
Common
stock
|
|
|
50
|
|
|
|
50
|
|
|
Additional paid-in
capital
|
|
|
214,538
|
|
|
|
213,313
|
|
|
Accumulated other
comprehensive loss
|
|
|
(9)
|
|
|
|
(32)
|
|
|
Accumulated
deficit
|
|
|
(178,853)
|
|
|
|
(168,335)
|
|
|
Total stockholders'
equity
|
|
|
35,726
|
|
|
|
44,996
|
|
|
Total liabilities and
stockholders' equity
|
|
$
|
45,390
|
|
|
$
|
53,168
|
|
|
Intermolecular, Inc.
|
|
Condensed
Consolidated Statements of Cash Flows
|
|
(In thousands,
Unaudited)
|
|
|
|
Nine Months Ended
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(10,519)
|
|
|
$
|
(12,444)
|
|
|
Adjustments to
reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
|
Depreciation,
amortization and accretion
|
|
|
5,369
|
|
|
|
7,708
|
|
|
Stock-based
compensation
|
|
|
1,221
|
|
|
|
2,936
|
|
|
(Gain) loss on
disposal of property and equipment
|
|
|
70
|
|
|
|
(19)
|
|
|
Gain on disposal of
intangible assets
|
|
|
(1,239)
|
|
|
|
—
|
|
|
Changes in operating
assets and liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
1,587
|
|
|
|
2,524
|
|
|
Prepaid expenses and
other assets
|
|
|
402
|
|
|
|
118
|
|
|
Materials
inventory
|
|
|
391
|
|
|
|
489
|
|
|
Accounts
payable
|
|
|
688
|
|
|
|
(453)
|
|
|
Accrued and other
liabilities
|
|
|
370
|
|
|
|
(2,088)
|
|
|
Deferred
revenue
|
|
|
485
|
|
|
|
(471)
|
|
|
Net cash used in
operating activities
|
|
|
(1,175)
|
|
|
|
(1,700)
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
|
|
Purchase of
investments
|
|
|
(15,505)
|
|
|
|
(22,361)
|
|
|
Redemption of
investments
|
|
|
20,014
|
|
|
|
23,526
|
|
|
Purchase of property
and equipment
|
|
|
(705)
|
|
|
|
(2,130)
|
|
|
Proceeds from sale of
equipment
|
|
|
12
|
|
|
|
22
|
|
|
Proceeds from sale of
intangible assets
|
|
|
1,500
|
|
|
|
—
|
|
|
Purchased and
capitalized intangible assets
|
|
|
—
|
|
|
|
(45)
|
|
|
Net cash (used in)
provided by investing activities
|
|
|
5,316
|
|
|
|
(988)
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
|
|
Payment of capital
leases
|
|
|
(13)
|
|
|
|
(7)
|
|
|
Proceeds from exercise
of common stock options
|
|
|
—
|
|
|
|
714
|
|
|
Net cash (used in)
provided by financing activities
|
|
|
(13)
|
|
|
|
707
|
|
|
Net increase
(decrease) in cash and cash equivalents
|
|
|
4,128
|
|
|
|
(1,981)
|
|
|
Cash and cash
equivalents at beginning of period
|
|
|
5,759
|
|
|
|
11,676
|
|
|
Cash and cash
equivalents at end of period
|
|
$
|
9,887
|
|
|
$
|
9,695
|
|
|
Intermolecular, Inc.
|
|
Reconciliation of
GAAP to Non-GAAP Financial Measures
|
|
(In thousands,
except per share amounts and percentages, Unaudited)
|
|
|
|
Three Months
Ended
September 30,
|
|
|
Nine Months
Ended
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
GAAP cost of net
revenue
|
|
$
|
2,875
|
|
|
$
|
3,456
|
|
|
$
|
8,409
|
|
|
$
|
12,384
|
|
|
Stock-based
compensation expense (a)
|
|
|
(38)
|
|
|
|
(101)
|
|
|
|
(144)
|
|
|
|
(408)
|
|
|
Non-GAAP cost of net
revenue
|
|
$
|
2,837
|
|
|
$
|
3,355
|
|
|
$
|
8,265
|
|
|
$
|
11,976
|
|
|
GAAP gross
profit
|
|
$
|
5,747
|
|
|
$
|
7,118
|
|
|
$
|
18,246
|
|
|
$
|
24,437
|
|
|
Stock-based
compensation expense (a)
|
|
|
38
|
|
|
|
101
|
|
|
|
144
|
|
|
|
408
|
|
|
Non-GAAP gross
profit
|
|
$
|
5,785
|
|
|
$
|
7,219
|
|
|
$
|
18,390
|
|
|
$
|
24,845
|
|
|
As a percentage of
net revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP gross
margin
|
|
|
66.7
|
%
|
|
|
67.3
|
%
|
|
|
68.5
|
%
|
|
|
66.4
|
%
|
|
Non-GAAP gross
margin
|
|
|
67.1
|
%
|
|
|
68.3
|
%
|
|
|
69.0
|
%
|
|
|
67.5
|
%
|
|
GAAP operating
loss
|
|
$
|
(1,962)
|
|
|
$
|
(6,912)
|
|
|
$
|
(10,943)
|
|
|
$
|
(12,764)
|
|
|
Stock-based
compensation expense (a):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Cost of net
revenue
|
|
|
38
|
|
|
|
101
|
|
|
|
144
|
|
|
|
408
|
|
|
- Research and
development
|
|
|
61
|
|
|
|
223
|
|
|
|
306
|
|
|
|
759
|
|
|
- Sales and
marketing
|
|
|
28
|
|
|
|
178
|
|
|
|
97
|
|
|
|
568
|
|
|
- General and
administrative
|
|
|
115
|
|
|
|
384
|
|
|
|
674
|
|
|
|
1,201
|
|
|
Non-GAAP operating
loss
|
|
$
|
(1,720)
|
|
|
$
|
(6,026)
|
|
|
$
|
(9,722)
|
|
|
$
|
(9,828)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
loss
|
|
$
|
(1,828)
|
|
|
$
|
(6,775)
|
|
|
$
|
(10,519)
|
|
|
$
|
(12,444)
|
|
|
Stock-based
compensation expense (a)
|
|
|
242
|
|
|
|
886
|
|
|
|
1,221
|
|
|
|
2,936
|
|
|
Non-GAAP net
loss
|
|
$
|
(1,586)
|
|
|
$
|
(5,889)
|
|
|
$
|
(9,298)
|
|
|
$
|
(9,508)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
loss
|
|
$
|
(1,828)
|
|
|
$
|
(6,775)
|
|
|
$
|
(10,519)
|
|
|
$
|
(12,444)
|
|
|
Interest income
(expense), net
|
|
|
70
|
|
|
|
51
|
|
|
|
182
|
|
|
|
123
|
|
|
Provision for
taxes
|
|
|
—
|
|
|
|
3
|
|
|
|
1
|
|
|
|
7
|
|
|
Depreciation,
amortization, impairments and accretion
|
|
|
1,772
|
|
|
|
3,885
|
|
|
|
5,369
|
|
|
|
7,708
|
|
|
Restructuring charges
(b)
|
|
|
—
|
|
|
|
1,120
|
|
|
|
1,351
|
|
|
|
1,120
|
|
|
Stock-based
compensation expense (a)
|
|
|
242
|
|
|
|
886
|
|
|
|
1,221
|
|
|
|
2,936
|
|
|
Adjusted
EBITDA
|
|
$
|
116
|
|
|
$
|
(932)
|
|
|
$
|
(2,759)
|
|
|
$
|
(796)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in
computing GAAP basic and diluted earnings per share
|
|
|
49,555
|
|
|
|
49,466
|
|
|
|
49,543
|
|
|
|
49,367
|
|
|
GAAP earnings per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net
loss per share
|
|
$
|
(0.04)
|
|
|
$
|
(0.14)
|
|
|
$
|
(0.21)
|
|
|
$
|
(0.25)
|
|
|
Shares used in
computing Non-GAAP basic and diluted earnings per share
|
|
|
49,555
|
|
|
|
49,466
|
|
|
|
49,543
|
|
|
|
49,367
|
|
|
Non-GAAP earnings per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net
loss per share
|
|
$
|
(0.03)
|
|
|
$
|
(0.12)
|
|
|
$
|
(0.19)
|
|
|
$
|
(0.19)
|
|
|
|
|
(a)
|
Stock-based
compensation reflects expense recorded relating to stock-based
awards. The Company excludes this item when it evaluates the
continuing operational performance of the Company, as management
believes this provides it a meaningful understanding of its core
operating performance.
|
|
|
|
(b)
|
Restructuring charges
incurred in connection with a reduction in headcount primarily
comprised of employee severance and benefit costs.
|
|
Intermolecular, Inc.
|
|
Fourth Quarter 2017
Outlook
|
|
Reconciliation of
GAAP Net Loss to Non-GAAP Net Loss
|
|
(In thousands,
except per share amounts, Unaudited)
|
|
|
GAAP net loss
range
|
|
$(1,000)
- $(1,500)
|
|
Stock-based
compensation
|
|
$300 -
$300
|
|
Non-GAAP net loss
range
|
|
$(700) -
$(1,200)
|
|
|
|
|
GAAP and Non-GAAP
diluted shares
|
|
49,600
|
|
GAAP net loss per
share range
|
|
$(0.02) -
$(0.03)
|
|
Non-GAAP net loss per
share range
|
|
$(0.01) -
$(0.03)
|
CONTACT:
Bill Roeschlein
Intermolecular, Inc.
Chief Financial Officer
bill.roeschlein@intermolecular.com
+1.408.582.5415
View original content with
multimedia:http://www.prnewswire.com/news-releases/intermolecular-announces-third-quarter-2017-financial-results-300548684.html
SOURCE Intermolecular, Inc.